Trial results for KaloBios Pharmaceuticals disappoint
January 07, 2015 at 15:17 PM EST
KaloBios
Pharmaceuticals Inc. (Nasdaq: KBIO) reported disappointing results from a
Phase 2 study of KB001-A to treat Pseudomonas aeruginosa lung infections
in subjects with cystic fibrosis sending the stock price plummeting $1.33 to close at $0.50.
